Skip to main content
SpringerLink
Log in

Resistente Tuberkulose

Zunehmende Probleme und Lösungsansätze

Drug-resistant tuberculosis

Growing problems and solutions

  • Leitthema
  • Published:
Der Pneumologe Aims and scope

Zusammenfassung

Die Medikamentenresistenz stellt bei der Tuberkulose (TB) ein zunehmendes Problem dar. Eine multiresistente (MDR-)TB wird bereits bei 440.000 Fällen, eine extensiv resistente (XDR-)TB bei 25.000 Fällen der weltweit über 9 Mio. jährlichen Neuerkrankungen angenommen. Um diese dramatische Entwicklung in den Griff zu bekommen, sind international konzertierte Anstrengungen notwendig, die sowohl die Therapie auf der Basis von Resistenztestungen als auch strikte Infektionsverhütungsmaßnahmen beinhalten müssen. Es mangelt jedoch an Laborkapazitäten, gerade in den am meisten betroffenen Ländern (China, Indien, frühere Sowjetunion), aber auch an ausreichend wirksamen Medikamenten, insbesondere bei der XDR-TB.

Abstract

Drug resistance is an increasing problem in the treatment of tuberculosis (TB). Multidrug-resistant (MDR-)TB is already assumed to be present in 440,000, extensively resistant (XDR-)TB in 25,000 of the nine million new TB cases worldwide per year. To gain control of this dramatic development, internationally concerted efforts are needed regarding both treatment regimens based on drug resistance tests and strict infection prevention measures. However, particularly the most affected countries (China, India, and the former Soviet Union) lack laboratory capacities, but also effective drugs, especially for XDR-TB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Aerts A, Hauer B, Wanlin M et al (2006) Tuberculosis and tuberculosis control in European prisons. Int J Tuberc Lung Dis 11:1213–1223

    Google Scholar 

  2. Blaas SH, Mütterlein R, Weig J et al (2008) Extensively drug resistant tuberculosis in a high income country: a report of four unrelated cases. BMC Infect Dis 8:60

    Article  PubMed  Google Scholar 

  3. Boehme CC, Nabeta P, Hillemann D (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363:1005–1015

    Article  CAS  PubMed  Google Scholar 

  4. Bone A, Aerts A, Grzemska M et al (2001) TB control in prisons. A manual for programme managers. WHO/CDS/TB/2000.281

  5. Caminero JA (2008) Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 12:869–877

    CAS  PubMed  Google Scholar 

  6. Caminero JA, Sotgin G, Zumla A et al (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10:621–629

    Article  CAS  PubMed  Google Scholar 

  7. Castell S, Hauer B, Brodhun B, Haas W (2010) Epidemiologie der Tuberkulose. Aktuelle Situation in Deutschland und weltweit. Pneumologe [Epub ahead of print]

  8. Chiang C-Y, Yew WW (2009) Multidrug-resistant and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 13:304–311

    PubMed  Google Scholar 

  9. Cohen T, Colijn C, Wright A et al (2008) Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med 177:1302–1306

    Article  PubMed  Google Scholar 

  10. Davies PDO (2003) The world wide increase in tuberculosis: how demographic change, HIV infection and increasing numbers in poverty are increasing tuberculosis. Ann Med 35:235–243

    Article  PubMed  Google Scholar 

  11. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (2001) Richtlinien zur medikamentösen Behandlung der Tuberkulose im Erwachsenen- und Kindesalter. Pneumologie 33:494–511

    Google Scholar 

  12. Dietze R, Hadad JD, McGee B et al (2008) Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 178:1180–1185

    Article  PubMed  Google Scholar 

  13. Eker B, Orzmann J, Migliori GB et al (2008) Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 14:1700–1706

    Article  PubMed  Google Scholar 

  14. Faustini A, Hall AJ, Perruci CA (2006) Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 61:158–163

    Article  CAS  PubMed  Google Scholar 

  15. Floyd K, Pantoja A (2008) Financial resources required for tuberculosis control to achieve global targets set for 2015. Bull World Health Organ 86:568–576

    Article  PubMed  Google Scholar 

  16. Forßbohm M, Loddenkemper R, Rieder HL (2003) Isoniazid resistance among tuberculosis patients by birth cohort in Germany. Int J Tuberc Lung Dis 7:973–979

    PubMed  Google Scholar 

  17. Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3:231–279

    Google Scholar 

  18. French CE, Glynn JR, Kruijshaar ME et al (2008) The association between HIV and antituberculosis drug resistance. Eur Respir J 32:718–725

    Article  CAS  PubMed  Google Scholar 

  19. Frieden TR, Sterling T, Pablos-Mendez A et al (1993) The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328:521–526

    Article  CAS  PubMed  Google Scholar 

  20. Gandhi NR, Moll A, Sturm AW (2006) Extensively drug resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575–1580

    Article  PubMed  Google Scholar 

  21. Gandhi NR, Shah NS, Andrews JR (2010) HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 181:80–86

    Article  PubMed  Google Scholar 

  22. Glynn JR, Kremer K, Borgdorff MW et al (2006) Beijing/W genotype Mycobacterium tuberculosis and drug resistance. European concerted action on new generation genetic markers and techniques for the epidemiology and control of tuberculosis. Emerg Infect Dis 12:736–743

    CAS  Google Scholar 

  23. Gupta R, Cegielski JP, Espinal MA et al (2002) Increasing transparency in partnerships for health – introducing the Green Light Committee. Trop Med Int Health 7:970–976

    Article  PubMed  Google Scholar 

  24. Hauer B, Kunitz F, Sagebiel D et al (2007) Übersicht zur DZK-Studie „Untersuchungen zur Tuberkulose in Deutschland: Molekulare Epidemiologie, Resistenzsituation und Behandlung“. In: Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (Hrsg). 30. Informationsbericht, Berlin, S 74–84

  25. Iseman MD (2002) Tuberculosis therapy: past, present and future. Eur Respir J 20(Suppl 36):87s–94s

    Article  Google Scholar 

  26. Kang MW, Kim HK, Choi YS (2010) Surgical treatment for multidrug-resistant and extensive drug-resistant tuberculosis. Ann Thorac Surg 89:1597–1602

    Article  PubMed  Google Scholar 

  27. Keshavjee S, Gelmanova I, Farmer PE et al (2008) Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 372:1403–1409

    Article  PubMed  Google Scholar 

  28. Kim DH, Kim HJ, Part S-K et al (2008) Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 178:1075–1082

    Article  CAS  PubMed  Google Scholar 

  29. Kliiman K, Altraja A (2009) Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 33:1085–1094

    Article  CAS  PubMed  Google Scholar 

  30. Kwon YS, Kim YH, Suh GY et al (2008) Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 47:496–502

    Article  PubMed  Google Scholar 

  31. Lange C, Grobusch MP, Wagner D (2008) Extensiv-resistente Tuberkulose (XDR-TB). Dtsch Med Wochenschr 133:374–376

    Article  CAS  PubMed  Google Scholar 

  32. Laserson KF, Thorpe LE, Leimane V et al (2005) Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9:640–645

    CAS  PubMed  Google Scholar 

  33. Leung CC, Rieder HL, Lange C, Yew WW (2010) Treatment of latent infection with M. tuberculosis: update 2010. Eur Respir J (Epub ahead of print, doi:10.1183/09031936.00079310)

  34. Loddenkemper R, Sagebiel D, Brendel A (2002) Strategies against multidrug-resistant tuberculosis. Eur Respir J 20(Suppl 36):66–77

    Article  Google Scholar 

  35. Loddenkemper R, Hauer B (2010) Resistente Tuberkulose. Große Herausforderung durch eine Weltepidemie. Dtsch Arztebl Int 107:10–19

    PubMed  Google Scholar 

  36. Migliori GB, Besozzi G, Girardi E et al (2007) Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 30:623–626

    Article  CAS  PubMed  Google Scholar 

  37. Migliori GB, Loddenkemper R, Blasi F et al (2007) 125 years after Robert Koch’s discovery of the tubercle bacillus. Is ‚science‘ enough to tackle the epidemic? Eur Respir J 29:423–427

    Article  CAS  PubMed  Google Scholar 

  38. Mitchison DA (1965) Chemotherapy of tuberculosis: a bacteriologist’s viewpoint. Br Med J 1:1333–1340

    Article  CAS  PubMed  Google Scholar 

  39. Mitnick CD, Shin SS, Seung KJ et al (2008) Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 359:563–574

    Article  CAS  PubMed  Google Scholar 

  40. Monedero I, Caminero JA (2010) Management of multidrug-resistant tuberculosis: an update. Ther Adv Respir Dis 4:117–127

    Article  PubMed  Google Scholar 

  41. Nachega JB, Chaisson RE (2003) Tuberculosis drug resistance: a global threat. Clin Infect Dis 36(Suppl 1):S24–S30

    Article  CAS  PubMed  Google Scholar 

  42. Nathanson E, Nunn P, Uplekar M et al (2010) MDR tuberculosis – critical steps for prevention and control. N Engl J Med 363:1050–1058

    Article  CAS  PubMed  Google Scholar 

  43. Nunn P, Reid A, De Cock KM (2007) Tuberculosis and HIV infection: the global setting. J Infect Dis 196:5–14

    Article  Google Scholar 

  44. Pai M, O’Brien R (2008) New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med 29:560–568

    Article  PubMed  Google Scholar 

  45. Parnish N, Carrol K (2008) Importance of improved TB diagnostics in addressing the extensively drug-resistant TB crisis. Future Microbiol 3:405–413

    Article  Google Scholar 

  46. Punga VV, Jakubowiak WM, Danilova ID et al (2009) Prevalence of extensively drug-resistant tuberculosis in Vladimir and Orel regions, Russia. Int J Tuberc Lung Dis 13:1309–1312

    CAS  PubMed  Google Scholar 

  47. Rajbhandary SS, Marks SM, Bock NN (2004) Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 8:1012–1016

    CAS  PubMed  Google Scholar 

  48. Raviglione MC, Uplekar MW (2006) WHO’s new Stop TB Strategy. Lancet 367:952–955

    Article  PubMed  Google Scholar 

  49. Richter E, Rüsch-Gerdes S, Hillemann D (2009) Drug-susceptibility testing in TB: current status and future prospects. Expert Rev Resp Med 3:497–510

    Article  CAS  Google Scholar 

  50. Robert Koch-Institut (2010) Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2008. Robert Koch-Institut, Berlin. http://www.rki.de

  51. Rüsch-Gerdes S, Hillemann D (2008) Moderne mykobakteriologische Labordiagnostik. Pneumologie 62:533–540

    Article  PubMed  Google Scholar 

  52. Scholten JN, Vlas SJ de, Zaleskis R (2008) Under-reporting of HIV infection among cohorts of TB patients in the new WHO European Region, 2003–2004. Int J Tuberc Lung Dis 12:85–91

    CAS  PubMed  Google Scholar 

  53. Schwalbe N, Harrington P (2002) HIV and tuberculosis in the former Soviet Union. Lancet 360:19–20

    Article  Google Scholar 

  54. Shah NS, Pratt R, Armstrong L (2008) Extensively drug-resistant tuberculosis in the United States, 1993–2007. JAMA 300:2153–2160

    Article  CAS  PubMed  Google Scholar 

  55. Small PM, Pai M (2010) Tuberculosis diagnosis – time for a game change. (Editorial) N Engl J Med 363:1070–1071

    Google Scholar 

  56. Sotgiu G, Ferrara G, Matteelli A et al (2009) Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 33:871–881

    Article  CAS  PubMed  Google Scholar 

  57. Vareldzis BP, Grosset J, Kantor IN de et al (1994) Drug-resistant tuberculosis, laboratory issues. WHO recommendations. Int J Tuberc Lung Dis 75:1–7

    Article  CAS  Google Scholar 

  58. Van Deun A, Maug AK, Salim MA (2010) Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 182:684–692

    Google Scholar 

  59. Velayati AA, Masjedi MR, Farnia P et al (2009) Emergence of new forms of totally drug-resistant tuberculosis bacilli. Chest 136:420–425

    Article  PubMed  Google Scholar 

  60. World Health Organization (2000) Guidelines for establishing DOTS-Plus projects for the management of multidrug-resistant tuberculosis (MDR-TB). World Health Organization, WHO/CDS/TB/2000.278. Geneva, Switzerland

  61. WHO Regional Office for Europe (2007) Status paper on prisons and tuberculosis. WHO, Kopenhagen, Dänemark. EUR/07/5063912

  62. World Health Organization (2008) Anti-tuberculosis drug resistance in the world. Report No. 4. WHO/HTM/TB/2008:394

  63. World Health Organization (2010) Multidrug- and extensively drug-resistant TB (M/XDR-TB). 2010 Global report on surveillance and response. WHO, Geneva, Switzerland. WHO/HTM/TB/2010.3

  64. World Health Organization (2008) The Stop TB Strategy. Building on and enhancing DOTS to meet the TB-related Millennium Development Goals. World Health Organization, Geneva, WHO/HTM/STB/2008

  65. World Health Organization (2009) Global tuberculosis control. A short update to the 2009 report. WHO, Geneva, Switzerland, WHO/HTM/TB/2009.426

  66. World Health Organization (2008) Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008:402

  67. World Health Organization (2009) Global tuberculosis control: epidemiology, strategy, financing. WHO, Geneva, Switzerland, WHO/HTM/TB2009.411

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Abteilung für Infektionsepidemiologie, Robert-Koch-Institut, Berlin, Deutschland

    B. Hauer

  2. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose, Stralauer Platz 34, 10243, Berlin, Deutschland

    S. Castell &  R. Loddenkemper

Authors
  1. B. Hauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Castell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Loddenkemper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Loddenkemper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hauer, B., Castell, S. & Loddenkemper, R. Resistente Tuberkulose. Pneumologe 8, 25–31 (2011). https://doi.org/10.1007/s10405-010-0401-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-010-0401-6

Schüsselwörter

Keywords

Search

Navigation